I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

Rhea-AI Summary

I-Mab (Nasdaq: IMAB) will hold a conference call on May 27 at 8 a.m. EST to present preliminary data from its ongoing phase 2 clinical trial of uliledlimab (TJD5), a differentiated CD73 antibody. This compound aims to enhance anti-tumor immune responses in combination with established checkpoint therapies. The call will also outline the global clinical development plan for uliledlimab, which is positioned to potentially offer significant clinical benefits in immuno-oncology.

Positive

• I-Mab is progressing to the phase 2 trial of uliledlimab, showcasing its commitment to innovative treatments.
• Uliledlimab may improve anti-tumor responses when used with PD-(L)1 therapies, which could expand its market potential.

Negative

• None.

SHANGHAI and GAITHERSBURG, MD., May 19 , 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq" IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will hold a call with investors at 8 a.m. EST on May 27^th to present preliminary data from an ongoing phase 2 clinical trial of its differentiated CD73 antibody uliledlimab (also known as TJD5, or TJ004309) and the global clinical development plan.

I-Mab Conference Call Information

Investors and analysts are invited to join the conference call at 8 a.m. EST on May 27^th via Zoom:

Meeting URL: https://i-mabbiopharma.zoom.us/j/84961586624?pwd=TVQ0SUtyMUl6d2dZbHgybGVScGwvUT09 
Meeting ID:    849 6158 6624
Password:       160619

About Uliledlimab (TJD5)

Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine.  Adenosine in turn binds to adenosine receptors on relevant immune cells and inhibits anti-tumor immune responses in tumor microenvironment. Uliledlimab is expected to offer clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Uliledlimab is effective in anti-tumor activities through a unique intra-dimer binding, leading to differentiated and favorable functional properties as evident in preclinical studies.

About I-Mab

I-Mab (Nasdaq: IMAB) is an innovation-driven global biopharma company focused on the discovery, development and commercialization of novel and highly differentiated biologics for immuno-oncology diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's globally competitive pipeline of more than 20 clinical and preclinical-stage drug candidates is driven by its internal discovery and global partnerships for in-licensing, based on the Company's Fast-to-Proof-of-Concept and Fast-to-Market development strategies. The Company is progressing from a clinical-stage biotech company into an innovative global specialty biopharmaceutical company with cutting-edge R&D capabilities, a world-class GMP manufacturing facility, and commercial capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States.  For more information, please visit http://www.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter, and WeChat.

I-Mab Contacts

Richard Yeh Chief Operating Officer IR@i-mabbiopharma.com

Gigi Feng Chief Communications Officer PR@i-mabbiopharma.com

Investor Inquiries:

The Piacente Group, Inc.
Emilie Wu
E-mail: emilie@thepiacentegroup.com
Office line: +86 21 6039 8363

View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-hold-investor-call-to-report-latest-phase-2-clinical-data-of-its-differentiated-cd73-antibody-uliledlimab-301551022.html

SOURCE I-Mab

FAQ

What is the purpose of I-Mab's phase 2 clinical trial for uliledlimab?

The trial aims to evaluate the efficacy of uliledlimab in enhancing anti-tumor immune responses, particularly in conjunction with checkpoint inhibitors.

What date is I-Mab's investor call to report on uliledlimab?

The investor call is scheduled for May 27 at 8 a.m. EST.

What can we expect from the preliminary data of uliledlimab?

The preliminary data will provide insights into uliledlimab's effectiveness and its potential role in immuno-oncology treatment regimens.

How could uliledlimab impact I-Mab's market position?

If successful, uliledlimab could enhance I-Mab's portfolio and strengthen its position in the competitive immuno-oncology market.